PTGX

Protagonist Therapeutics Inc.

Price

$140.32

return (12m)

116.44%

p/e

111.59

p/bv

10.99

DIVIDEND YIELD

0.00%

PTGX price

Protagonist Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PTGX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-3.93%

3 months

7.73%

1 year

116.44%

2 years

216.46%

5 years

690.54%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals PTGX

Valuation

P/E

111.59

Sector -3.46

Industry -3.46

P/BV

10.99

Sector 1.94

Industry 1.94

P/Revenue (PSR)

32.81

Sector 1.96

Industry 1.96

EV/EBITDA

53.21

Sector -216.42

Industry -216.42

EV/EBIT

53.35

Sector -46.11

Industry -46.11

P/EBITDA

154.50

Sector -21.02

Industry -21.02

P/EBIT

158.58

Sector -27.60

Industry -27.60

P/Total Assets

10.45

Sector 1.14

Industry 1.14

P/Net Current Assets

12.12

Sector -10.24

Industry -10.24

P/Working Capital

12.02

Sector -162.19

Industry -162.19

EPS

1.26

Sector -1.78

Industry -1.78

BVPS

12.76

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

100.00%

Sector 41.35%

Industry 41.35%

EBITDA Margin

74.56%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

74.37%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

20.69%

Sector -35.47%

Industry -35.47%

Net Profit Margins

29.40%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.24

Sector 0.03

Industry 0.03

Profitability

ROE

9.85%

Sector -57.40%

Industry -57.40%

ROA

9.36%

Sector -59.43%

Industry -59.43%

ROIC

559.05%

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

21.71

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-4.92

Sector -21.98

Industry -21.98

Net Debt / EBIT

-4.93

Sector -8.44

Industry -8.44

Net Debt / Equity

-0.93

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.95

Sector 0.46

Industry 0.46

Liabilities/Assets

0.05

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

59.45%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals PTGX

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Protagonist Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$140.32

Fair Value

$19.02

Upside

-86.45%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PTGX Protagonist Therapeutics Inc.	$140.32	119.25%	0.00%	111.59	10.99	9.85%	29.40%
PFE Pfizer Inc.	$27.48	8.11%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$259.97	9.77%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.23	-33.47%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$143.18	65.09%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$156.59	-4.79%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.33	34.59%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$69.46	-51.82%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$402.15	38.44%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$729.88	22.13%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.98	45.42%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$888.29	16.56%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$501.27	24.01%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$226.17	45.05%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$914.13	19.13%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.41	46.40%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$220.34	42.87%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PTGX - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Protagonist Therapeutics

Protagonist Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

20 years

Founded: 2006

2016

Time since IPO - 10 years

79

Employees

Protagonist Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $9.25 billion, with shareholders equity totaling $841.54 million.

The company employs approximately 79 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Protagonist Therapeutics Inc. reported $281.99 million in revenue, generating net income of $82.91 million.

Key financial metrics include a P/E ratio of 111.59, a price-to-book (P/B) ratio of 10.99, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PTGX.

Market cap

$9.25 billion

Net worth

$841.54 million

$841,543,000.00

Assets

$885.54 million

$885,544,000.00

Total Shares Outstanding

65.94 million

65,935,000

Average Daily Trading Volume

$585.12 Thousand

$585,115.88

Sector

Health Care

Industry

Biotechnology

PTGX

PTGX revenue and profits

Financial Results PTGX

DRAG THE FRAME TO SEE MORE DATA

PTGX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$888.29 20,83% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$226.17 47,96% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$259.97 14,69% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$143.18 65,85% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$156.59 --6,84% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$27.48 7,47% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$888.29 20,83% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$226.17 47,96% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$259.97 14,69% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$143.18 65,85% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$156.59 --6,84% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$27.48 7,47% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Protagonist Therapeutics (PTGX) today?

The current price of Protagonist Therapeutics (PTGX) is $140.32. The stock began the year trading around $87.34 and is currently priced at $140.32. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Protagonist Therapeutics (PTGX) pay dividends?

Protagonist Therapeutics (PTGX) did not pay dividends over the past year.

Is Protagonist Therapeutics (PTGX) a good investment?

Protagonist Therapeutics (PTGX) is currently trading at $140.32 with a P/E ratio of 111.59. This represents a 1,115% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 116.44%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Protagonist Therapeutics (PTGX) stock?

You can buy Protagonist Therapeutics (PTGX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol PTGX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Protagonist Therapeutics (PTGX) yield today?

Over the past month, Protagonist Therapeutics (PTGX) has returned -3.93% — 116.44% over the past year, and 690.54% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Protagonist Therapeutics (PTGX) today at the current price of $140.32 your total investment would be $14,032.00.

Based on historical performance, the investment would have grown to approximately:

$30,370.86 after 1 year
$110,928.57 after 5 years
$14,032.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PTGX

Protagonist Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PTGX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING PTGX WITH OTHER STOCK

ABOUT Protagonist Therapeutics

Protagonist Therapeutics Inc.

United States

20 years

2016

79

PROFIT X PRICE PTGX

Financial Results PTGX

PTGX cash flow

Asset, Revenue and Profit Growth - PTGX

PTGX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions